About Silica Corpora
Silica Corpora is a company specialized in holistic antibody design using a powerful AI platform to design antibody candidates for in-demand therapies.
Founded in 2022 by Tim Ermak and Jaime Rosselló, the company is focused on transforming drug discovery with generative technologies. In 2023, they added Anna-Catharina Krebs as Chief Scientific Officer to accelerate platform development.
Mission and Technology
The company uses a proprietary AI-based platform to design and optimize therapeutic antibodies targeting priority diseases. Their modular system uses AI, machine learning, and data analytics working exclusively with amino acid sequences.
They have multiple technology modules: Generator, Discriminator, Optimizer, and Ep-Mapper, each with specific roles from generating antibody candidates to predicting properties and optimizing sequences.
Silica Corpora aims to develop advanced De Novo solutions for higher quality and more cost-effective antibody therapeutics for diseases with high unmet need.
Collaborations
They have strategic partnerships with entities such as Berkeley Skydeck, SIB, Charite, Google Cloud, Exist, Fraunhofer, and others to drive innovation and expand impact.